

Gabather

Press release 20190710

Gabather AB expands intellectual property portfolio related to the clinical candidate GT-002

Gabather AB is pleased to announce a further advance in its intellectual property portfolio. Gabather's international Patent Cooperation Treaty (PCT) patent application, submitted in December 2017, related to the improved synthesis process for the large-scale manufacture of triazoloquinazolinones, including its GT-002 clinical drug candidate as WO 2019/123011. The application will next enter the PCT National Phases undergoing examination in individual countries in the EU as well as the USA, India, Japan and China . The filing of PCT national phase patent applications is due by July 2020.

"The improved synthesis process for large-scale manufacturing allows a more efficient and high yield production of GT-002 and related compounds, which is important when producing large quantities of drug product for future clinical trials and furthermore it gives Gabather, if approved, extended patent protection and exclusivity for this compound series on the market", says CEO Michael-Robin Witt

Gabather AB

Michael-Robin Witt, CEO

E-mail: mrw@gabather.com

Phone nr: 0736872839

About Gabather AB (publ)

Gabather was founded in 2014, based on 10 years research at Lund University and Research Institute of Biological Psychiatry in Roskilde, to develop new drug candidates for the treatment of CNS diseases. Gabather was founded by Forskarpatent I Syd AB and inventors Olov Sterner and Mogens Nielsen, with the purpose of commercializing Sterner's and Nielsen's inventions. Sterner has worked with medicinal chemistry for 40 years, and Nielsen has worked in neuroscience for 45 years.

Gabather is listed on Nasdaq First North and Certified Advisor is Erik Penser Bank (+46 (0) 8-463 83 00) or certifiedadviser@penser.se.

Forward-looking statement

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.